AYTU vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AYTU vs LLY: Head-to-Head Comparison
This page compares Aytu BioPharma, Inc. (AYTU) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.